REVATIO APPROVED TO TREAT RARE AND INCURABLE DISEASE

Pfizer Canada announced that it has received Health Canada approval for Revatio (sildenafil citrate), an important new treatment for pulmonary arterial hypertension (PAH), a rare and incurable vascular disease. Sildenafil citrate is also the active ingredient in Viagra, Pfizer's revolutionary treatment for erectile dysfunction, which has been used by more than 27 million men worldwide since it was first introduced in 1998. CNW Group (http://www.newswire.ca/en/releases/archive/August2006/22/c7333.html)